3/20
04:32 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
3/20
04:20 pm
mcrb
Rating for MCRB
Low
Report
Rating for MCRB
3/14
01:58 pm
mcrb
Rating for MCRB
Low
Report
Rating for MCRB
3/14
01:58 pm
mcrb
Rating for MCRB
Low
Report
Rating for MCRB
3/14
01:58 pm
mcrb
Rating for MCRB
Low
Report
Rating for MCRB